InMed Pharmaceuticals Inc
INM
Company Profile
Business description
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer’s disease, INM-089’s pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
Contact
885 West Georgia Street
Suite 1445
VancouverBCV6C 3E8
CANT: +1 604 669-7207
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
30 June 2026
Employees
13
Stocks News & Analysis
stocks
How I lost all my savings through a poor investment decision
With first timers at risk of poor investment decisions and an interest in speculative stocks, I explore my biggest investing mistake.
stocks
Chart of the Week: Morningstar’s forecast for CSL’s future
We see gross margin expansion on efficiencies and limited tariff impact
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,063.40 | 33.90 | 0.38% |
| CAC 40 | 7,795.42 | 32.03 | -0.41% |
| DAX 40 | 23,534.83 | 131.98 | -0.56% |
| Dow JONES (US) | 46,053.51 | 67.77 | -0.15% |
| FTSE 100 | 9,213.98 | 36.45 | -0.39% |
| HKSE | 26,484.68 | 33.97 | -0.13% |
| NASDAQ | 22,425.38 | 72.47 | -0.32% |
| Nikkei 225 | 45,754.93 | 124.62 | 0.27% |
| NZX 50 Index | 13,153.79 | 27.52 | -0.21% |
| S&P 500 | 6,613.86 | 24.11 | -0.36% |
| S&P/ASX 200 | 8,773.00 | 35.10 | 0.40% |
| SSE Composite Index | 3,853.30 | 0.34 | -0.01% |